Products for Research Use Only
RegisterLogin

Rigosertib (sodium)

CAT: 0804-HY-12037-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12037-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle[1][2]. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM[3].
CAS Number
592542-60-4
Product Name Alternative
ON-01910 (sodium)
UNSPSC
12352005
Target
Apoptosis; PI3K; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Rigosertib-sodium.html
Purity
99.57
Solubility
DMSO : 150 mg/mL (ultrasonic) |H2O : ≥ 52 mg/mL
Smiles
COC1=CC=C(C=C1NCC(O[Na])=O)CS(/C=C/C2=C(C=C(C=C2OC)OC)OC)(=O)=O
Molecular Formula
C21H24NNaO8S
Molecular Weight
473.47
References & Citations
[1]Xu F, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signalingtransduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310.|[2]Hyoda T, et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015 Mar;106 (3) :287-93.|[3]Gumireddy K, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005 Mar;7 (3) :275-86.|[4]Reddy MV, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E) -2-{2-methoxy-5-[ (2',4',6'-trimethoxystyrylsulfonyl) methyl]phenylamino}acetate (ON 01910.Na) : synthesis, structure-activity relationship, and biological activity. J Med Chem.|[5]Chapman CM, et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res. 2012 Apr 1;18 (7) :1979-91
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PLK1; PLK2
Citation 01
Harvard Medical School LINCS LIBRARY|Harvard Medical School LINCS LIBRARY|Int J Biol Sci. 2020 Jun 27;16 (13) :2382-2391.|Oncogenesis. 2025 Mar 1;14 (1) :4.|Oncol Res. 2021 Sep 7;28 (7) :745-761.|Sci Rep. 2017 Aug 17;7 (1) :8629. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.

Related Products

CatalogName
HY-12037A-01Rigosertib
HY-N15194AInostamycin A (sodium)
HY-166084Docosatetraenoate (sodium)
HY-16366ABriciclib (sodium)
HY-150364AFarabursen (sodium)
HY-107943Tyropanoate (sodium)
HY-W009640AMofebutazone (sodium)
HY-22274-01DMPG (sodium)
HY-17474A-01Parecoxib (Sodium)
HY-148089A-01Eplontersen (sodium)

Alternative Products

CatalogName
GTR19169487-01Rigosertib sodium
A1404-100Rigosertib sodium salt
A21824-200Rigosertib sodium 200mg
A21824-10Rigosertib sodium 10mg
A21824-5Rigosertib sodium 5mg
GTR19164256-01Rigosertib sodium (b)
A21824-50Rigosertib sodium 50mg
A21824-25Rigosertib sodium 25mg
A21824-100Rigosertib sodium 100mg
BUP13084-01(E/Z) -Rigosertib sodium

Popular Products